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Background-—Patients with type 2 diabetes mellitus and elevated urinary albumin:creatinine ratio (ACR) have increased risk of
heart failure. We hypothesized this was because of cardiac tissue changes rather than silent coronary artery disease.
Methods and Results-—In a case-controlled observational study 130 subjects including 50 ACR+ve diabetes mellitus patients with
persistent microalbuminuria (ACR >2.5 mg/mol in males and >3.5 mg/mol in females, ≥2 measurements, no previous renin–
angiotensin–aldosterone therapy, 50 ACRve diabetes mellitus patients and 30 controls underwent cardiovascular magnetic
resonance for investigation of myocardial ﬁbrosis, ischemia and infarction, and echocardiography. Thirty ACR+ve patients
underwent further testing after 1-year treatment with renin–angiotensin–aldosterone blockade. Cardiac extracellular volume
fraction, a measure of diffuse ﬁbrosis, was higher in diabetes mellitus patients than controls (26.13.4% and 23.33.0%
P=0.0002) and in ACR+ve than ACRve diabetes mellitus patients (27.24.1% versus 25.12.9%, P=0.004). ACR+ve patients
also had lower E0 measured by echocardiography (8.21.9 cm/s versus 8.91.9 cm/s, P=0.04) and elevated high-sensitivity
cardiac troponin T 18% versus 4% ≥14 ng/L (P=0.05). Rate of silent myocardial ischemia or infarction were not inﬂuenced by ACR
status. Renin–angiotensin–aldosterone blockade was associated with increased left ventricular ejection fraction (59.37.8 to
61.58.7%, P=0.03) and decreased extracellular volume fraction (26.53.6 to 25.23.1, P=0.01) but no changes in diastolic
function or high-sensitivity cardiac troponin T levels.
Conclusions-—Asymptomatic diabetes mellitus patients with persistent microalbuminuria have markers of diffuse cardiac ﬁbrosis
including elevated extracellular volume fraction, high-sensitivity cardiac troponin T, and diastolic dysfunction, which may in part be
reversible by renin–angiotensin–aldosterone blockade. Increased risk in these patients may be mediated by subclinical changes in
tissue structure and function.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01970319. ( J Am Heart Assoc. 2017;6:
e005539. DOI: 10.1161/JAHA.117.005539.)
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T ype 2 diabetes mellitus is well established as anindependent risk factor for the development of heart
failure and does not appear to show a relationship with
conventional risk factors including age, sex, existing coronary
artery disease (CAD), and hypertension.1 Patients with
diabetes mellitus and heart failure have a poor clinical
prognosis with higher mortality than normoglycemic heart
failure patients.2,3 Epidemiological evidence suggests that
poor control of blood glucose in type 2 diabetes mellitus is
associated with increased rate of heart failure.4 However, data
from randomized controlled trials demonstrate that intensive
control of glucose does not reduce the risk of hospitalization
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for heart failure.5 To complicate matters, recent evidence
suggests that certain hypoglycemic agents used can modulate
the risk of heart failure in patients with diabetes mellitus,
independently of glucose-lowering properties.6–8
Patients with type 2 diabetes mellitus and albuminuria
have higher risk of heart failure,9,10 and treatment directed
at modulating the renin–angiotensin–aldosterone system
(RAAS) decreases rate of hospitalization with cardiac
decompensation. Data from several large randomized con-
trolled trials have shown that elevated albumin:creatinine
ratio (ACR) is associated with increased risk of new-onset
heart failure.11 Furthermore, RAAS modulation with either an
angiotensin-converting enzyme (ACE) inhibitor or angiotensin
receptor blocker decreases the risk of heart failure
hospitalization.12,13
Multiparametric cardiovascular imaging has been used to
detect subclinical changes in cardiac structure and function in
type 2 diabetes mellitus including increased left ventricular
(LV) mass, concentric remodeling of the left ventricle,14–16
and diastolic dysfunction as measured by conventional
Doppler and tissue Doppler echocardiography.17,18 Cardio-
vascular magnetic resonance (CMR) T1 mapping studies have
also suggested that type 2 diabetes mellitus is associated
with diffuse ﬁbrosis and increased cardiac extracellular
volume fraction (ECV).19–21
In addition, several cardiovascular imaging methods have
been used to show that type 2 diabetes mellitus is associated
with increased rates of CAD,22 silent myocardial ischemia,23
and silent myocardial infarction (MI) .24–26 Patients with type
2 diabetes mellitus have elevated levels of cardiac biomarkers
including high-sensitivity cardiac troponin T (hs-cTnT) and
amino terminal B type natriuretic peptide (NT-proBNP), which
appear to be associated with adverse cardiovascular out-
comes including heart failure.27–29
Given that the exact pathogenic mechanisms for heart
failure in diabetes mellitus remain unclear, we aimed, through
a combination of an observational and interventional study, to
establish the pattern of subclinical cardiac disease in patients
with diabetes mellitus and persistent microalbuminuria and
determine whether the risk of heart failure is mediated by
occult CAD or changes in cardiac structure and tissue
characteristics. The interventional part of the work investi-
gated whether detected abnormalities are reversible after
blockade of the RAAS.
Methods
Enrollment Criteria
The study was approved by the National Research Ethics
Service (13/YH/0098) and all participants gave informed
consent. A total of 100 patients with type 2 diabetes
mellitus were recruited from 30 primary care health centers
in the local area from August 2013 to March 2015. Fifty
consecutive patients with persistent microalbuminuria
(ACR+ve), urinary ACR >2.5 mg/mol in males and
>3.5 mg/mol in females, were recruited after their annual
diabetes mellitus check before commencement on an ACE
inhibitor in line with national guidelines.30 All ACR+ve
patients had laboratory ACR repeated within 4 months to
conﬁrm persistent microalbuminuria. In addition, 50
patients with type 2 diabetes mellitus were recruited who
had never had ACR above the thresholds (ACRve). This
group was prospectively matched by frequency matching
for age, sex, and clinic blood pressure to ACR+ve patients.
Exclusion criteria for all subjects were known cardiac
disease, kidney disease (estimated glomerular ﬁltration rate
<30 mL/min per 1.73 m2), uncontrolled hypertension, and
treatment with insulin or ACE inhibitor/angiotensin receptor
blocker. Ten-year likelihood of developing CAD and related
mortality were calculated using the Framingham risk
score.31 In addition, 30 age- and sex-matched controls
with no diabetes mellitus and no known cardiovascular
disease were recruited. The study was conducted in
accordance with the declaration of Helsinki and all subjects
gave informed written consent.
In accordance with current guidelines, all patients with
persistent microalbuminuria were started on an ACE inhibitor
by their primary care team following the baseline investiga-
tions30 and uptitrated to the maximum tolerated dose. Those
who could not tolerate an ACE inhibitor because of cough
were started on an angiotensin receptor blocker. All testing
was repeated after 1-year treatment with RAAS inhibition.
Clinical Perspective
What Is New?
• Asymptomatic diabetes mellitus patients with persistent
microalbuminuria have markers of diffuse cardiac ﬁbrosis
including elevated cardiac extracellular volume fraction,
high-sensitivity cardiac troponin T, and diastolic dysfunction,
which may in part be reversible by renin–angiotensin–
aldosterone blockade.
What Are the Clinical Implications?
• These ﬁndings suggest that increased risk in this patient
group is mediated by subclinical changes in tissue structure
and function rather than occult coronary artery disease.
Future randomized studies are needed to establish whether
extracellular volume fraction, high-sensitivity cardiac tro-
ponin T, or diastolic dysfunction themselves or the associ-
ated adverse prognosis can be altered by intervention.
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Echocardiography and Blood Pressure
Assessment
All patients underwent echocardiography (Vivid e9, GE
Medical Systems, Milwaukee, WI) focused on Doppler mea-
surements of mitral inﬂow and tissue Doppler imaging of the
lateral and medial mitral annulus for the assessment of
diastolic function. E/A ratio, E0, A0, and S0 were measured
using inbuilt software blinded to clinical details according to
international guidelines.32 All patients underwent 24-hour
blood pressure monitoring with a Welch-Allyn 6100 ambula-
tory blood pressure monitor.
CMR Protocol
Patients and controls underwent CMR using an identical
protocol on a dedicated cardiovascular 3 Tesla Philips Achieva
system equipped with a 32-channel coil and MultiTransmit
technology. Data were acquired during breath-holding at end
expiration. T1 maps were acquired in a midventricular slice.
Native T1 mapping used a breath-held Modiﬁed Look-Locker
Inversion recovery (MOLLI) acquisition (ECG triggered 5(3s)3,
spatial resolution 1.9891.98910 mm3 [reconstructed to
1.2591.25 mm2]), single-shot, SENSE factor 2, prepulse
delay 350 ms, trigger delay set for end-diastole (adaptive),
ﬂip angle 35°, acquisition duration per image 170 to 185 ms
(dependent on ﬁeld of view).
Next, myocardial perfusion CMR was planned in the same
3 short-axis slices using a spoiled turbo gradient-echo
sequence. This was performed while intravenous adenosine
was administered at 140 lg/kg per minute for 3 minutes
and repeated >10 minutes later at rest. Gadobutrol
(0.075 mmol/kg) was administered for each stress and rest
perfusion imaging (Gadovist, Bayer Pharma, Berlin,
Germany).
Cine images covering the entire heart in the LV short axis
(slice thickness 10 mm); left atrium in short axis (slice
thickness 5 mm) and in orthogonal long axis planes was
acquired. Late gadolinium enhancement (LGE) in matching LV
short- and long-axis planes was carried out more than
6 minutes after rest perfusion imaging as described
previously.26
Postcontrast T1 mapping was carried out exactly 15 min-
utes following last contrast injection using the identical
pulse sequence and planning as the native T1 map (above).
CMR Interpretation
CMR data were assessed quantitatively using commercially
available software (CVI42, Circle Cardiovascular Imaging
Inc, Calgary, Canada). Epicardial and endocardial borders
were traced ofﬂine on the LV cine stack at end-diastole and
end-systole to calculate end-diastolic, end-systolic LV
volumes, stroke volume, ejection fraction (EF), and LV
mass. Left atrial volume was calculated by tracing the left
atrial endocardial border at end-systole when the left atrium
was largest.
Pre- and postcontrast myocardial T1 values with a 3-
parameter exponential ﬁt with Look-Locker correction were
measured from the midventricular short-axis slice in the
septum. ECV was calculated from native and postcontrast T1
times of myocardium and blood pool and hematocrit as
previously reported excluding any areas of scar seen on LGE
imaging.33 Perfusion imaging was interpreted independently
by 2 physicians experienced in CMR for the presence of
clinically signiﬁcant ischemia (>1 segment of American Heart
Association 16 segment model).34 Mass of LGE was quanti-
ﬁed using the Otsu automated threshold method and divided
by LV mass calculated from short axis cines to give a
percentage of LV with LGE.35
Biomarker Assessment
Twenty milliliters of blood was drawn from each subject at the
time of each CMR. Full blood count, urea and electrolytes,
and hemoglobin A1c were measured at that time. Serum was
stored at 70°C and tested for hs-cTnT (typical coefﬁcient of
variability 4.4% at 13.7 ng/L and 3.6% at 95.3 ng/L), NT-
proBNP (typical coefﬁcient of variability 2.9% at 91 ng/L and
2.1% at 415 ng/L); Cobas 8000 (Roche Diagnostics, Burgess
Hill, West Sussex, UK) and aldosterone (typical between batch
coefﬁcient of variability <10% at 282, 402 and 1833 pmol/L);
local laboratory-validated radioimmunoassay. Patients with
hs-cTnT ≥14 ng/L and NT-proBNP ≥125 ng/L were deﬁned
as having elevated levels of these biomarkers that have been
independently associated with adverse outcomes in type 2
diabetes mellitus.27–29
Statistical Analysis and Power Calculations
Statistical analysis was performed using IBM SPSS Statistics
20.0 (IBM Corp, Armonk, NY). Continuous variables were
expressed as meanSD. Categorical variables were
expressed as N (%) and compared using Fisher exact test.
Shapiro–Wilk test was used to test normality and depending
on the result ANOVA and and Kruskal–Wallis test were used
to compare means of ACR+ve, ACRve, and controls. Paired t
test or Wilcoxon test were used to compare parameters
before and after treatment. P<0.05 was considered statisti-
cally signiﬁcant.
Based on reported difference in ECV between those with
and without diabetes mellitus,21 it was predicted that 49
patients per group were needed to detect a 2% difference in
ECV between ACR+ve and ACRve patients and that 26
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patients would be needed to detect a 2% change in ECV after
RAAS inhibition (assuming SD 3%, a=0.05, power=90%).
Results
Patient Characteristics
A total of 464 patients with diabetes mellitus were
approached, of whom 128 patients agreed to participate
with 50 ACR+ve and 50 ACRve completing the full
protocol (Figure 1). Six of 30 controls chose not to receive
adenosine stress because of potential side effects. Baseline
patient and control characteristics and medications are
shown in Table 1. There was no difference between ACR+ve
and ACRve patients in age, sex, body mass index, diabetes
mellitus duration, hemoglobin A1c, or 24-hour blood
pressure.
Effect of Diabetes Mellitus and Microalbuminuria
on Cardiac Structure and Composition
T1 mapping could be analyzed in all scans. At baseline,
native T1 and ECV were higher in patients with diabetes
mellitus than in controls (1242.253.9 ms versus
1209.747.4 ms, P=0.004 and 26.13.4% versus
23.33.0%, P=0.0002). Native T1 and ECV were also
higher in ACR+ve than ACRve patients (1252.666.0 ms
versus 1231.7235.8 ms, P=0.05 and 27.24.1% versus
25.12.9%, P=0.004) (Figure 2). A total of 17/100 patients
with diabetes mellitus had a subendocardial pattern of LGE
in keeping with prior silent MI compared with 0/30
controls, P=0.01. There was no difference in the rate of
MI between ACR+ve and ACRve patients (9/50 and 8/
50, respectively; P=0.79). Two of 50 ACR+ve and 2/50
ACRve patients had clinically signiﬁcant inducible
Figure 1. Recruitment ﬂowchart. ACEi indicates Angiotensin converting enzyme inhibitor; ACR, albumin:
creatinine ratio; ACR+ve, albumin:creatinine ratio positive; ACRve, albumin:creatinine ratio negative; CI,
contraindication; DM, diabetes mellitus; MRI, magnetic resonance imaging.
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Table 1. Subject Characteristics
Control ACRve ACR+ve
P Value Between
3 Groups
P Value for ACRve
and ACR+ve
N 30 50 50
Age (y) 59.111.5 61.19.1 60.212.7 0.76 0.69
Male sex, n (%) 21 (70) 42 (84) 40 (80) 0.32 0.60
Body mass index, kg/m2 26.63.2 28.64.0 29.14.6 0.04 0.61
Duration of diabetes mellitus (y)  4.64.4 5.34.4  0.40
HbA1c, mmol/mol 36.23.8 60.213.7 65.923.9 <0.0001 0.47
Systolic BP, mm Hg 13013 13013* 13317* 0.66 0.46
Diastolic BP, mm Hg 7011 718* 7410* 0.20 0.12
Total cholesterol  4.41.2 4.41.1  0.94
Smoking 0 6 9 0.40
Framingham 10-y risk of
coronary disease, %
 14.67.0 16.58.2 0.21
Framingham 10-y risk of
coronary mortality, %
 3.53.0 4.33.1 0.24
Metformin 0 49 38 <0.0001 0.002
Sulfonylurea 0 12 21 <0.0001 0.09
Gliptin 0 5 6 0.16 0.75
Other hypoglycemic 0 3 1 0.28 0.62
Insulin 0 0 0 1.0 1.0
ACE inhibitor 0 0 0 1.0 1.0
b-Blocker 0 1 3 0.28 0.62
Calcium channel blocker 1 6 4 0.40 0.74
Diuretic 0 2 3 0.40 1.0
Statin 2 36 33 <0.0001 0.67
Aspirin 3 4 14 0.01 0.02
LV EDV, mL 157.642.1 149.232.4 147.236.3 0.37 0.33
LV EDV index, mL/m2 81.018.8 74.113.9 73.114.5 0.11 0.29
LV ESV, mL 65.425.0 58.215.6 59.523.7 0.41 0.54
Ejection fraction, % 59.17.9 61.25.1 60.66.9 0.21 0.60
LV mass, g 93.523.6 93.917.6 98.523.3 0.07 0.39
LV mass index, g/m2 48.09.9 46.87.7 48.99.4 0.06 0.35
Mass/end diastolic volume, g/mL 0.600.11 0.650.14 0.680.12 <0.0001 0.07
Left atrial volume, mL 91.626.6 87.517.0 89.822.5 0.87 0.83
Left atrial volume index, mL/m2 46.912.3 43.78.2 44.99 0.56 0.58
Native T1, ms 121047 123236 125366 0.002 0.05†
Extracellular volume, % 23.33.0 25.12.9 27.24.1 <0.0001 0.004†
Myocardial infarction, n (%) 0 (0) 8 (16) 9 (18) 0.01‡ 0.79
Mass of infarction, g  3.12.1 8.711.7  0.50
Serum aldosterone, pmol/L  299195 323183  0.32
hs-cTnT ≥14 ng/L, n (%)  2 (4) 9 (18) 0.05†
NT-proBNP ≥125 ng/L, n (%)  4 (8) 7 (14) 0.52
E/A ratio  0.870.27 0.850.34 0.69
Continued
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ischemia on adenosine stress perfusion imaging. None of
the controls had inducible ischemia.
There were no signiﬁcant differences in LV EDV, ESV,
mass, EF, or left atrial volume between ACR+ve, ACRve, or
control (Table 1). Average E0 measured by echocardiography
was lower in ACR+ ve than ACRve patients (8.21.9 cm/s
versus 8.91.9 cm/s, P=0.04) but there was no signiﬁcant
difference in E/A ratio, average E/E0, or S0.
There was a trend to more ACR+ve than ACRve patients
having elevated hs-cTnT levels (18% versus 4%, P=0.05). No
difference was seen in the proportion of patients with
elevated NT-proBNP or serum aldosterone levels. Patients
with elevated hs-cTnT had signiﬁcantly elevated native T1 and
ECV (1293.380.2 ms and 1235.846.5 ms, P=0.0001 and
30.34.8% versus 25.63.2%, P<0.0001, respectively). In
patients with elevated NT-proBNP, ECV was higher
(29.34.5% versus 25.73.4%, P=0.002) but the difference
in native T1 did not reach signiﬁcance (1285.679.6 ms
versus 1236.847.8 ms, P=0.07).
RAAS Inhibition
Of the 50 ACR+ve patients recruited, 40 returned for follow-
up after 1 year (5 not willing to have the follow-up scan, 4 lost
to follow-up, and 1 died; Figure 1). Of the remaining 40
patients, 10 were not taking an ACE inhibitor or angiotensin
receptor blocker (patient compliance 5, hypotension 2, renal
dysfunction 1, hyperkalemia 1, planning pregnancy 1).
Therefore, 30 patients completed repeat imaging after a year
treatment with RAAS inhibition (median 369, interquartile
range 358–385 days). RAAS inhibition was prescribed accord-
ing to clinician preference and patient tolerance and included
ramipril in the majority (23 patients), perindopril in one
patient, losartan in 3, candesartan in 2, and irbesartan in a
single patient. The ﬁnal dose was equivalent to ramipril
4.62.9 mg.36,37
Treatment with RAAS inhibition was associated with a
signiﬁcant decrease in serum aldosterone level (337.0192.7
to 244.3137 pmol/L, P=0.03) but the change in 24-hour
blood pressure was not statistically signiﬁcant (Table 2).
Effect of ACE Inhibition on Cardiac Structure,
Function, and Composition
After 1-year treatment with RAAS inhibition 14/30 (47%) had
a decrease in ACR to the extent they would no longer be
considered ACR+ve. RAAS inhibition was associated with a
decrease in ECV (26.53.6 to 25.23.1%, P=0.01) but not
native T1 (1243.058.5 to 1251.440.9 ms, P=0.44). There
was also a signiﬁcant decrease in LV EDV (148.438.7 to
138.937.3 mL, P=0.001) and an associated increase in LV
EF (59.37.8 to 61.58.7%, P=0.03) but there was no
signiﬁcant change in LV mass or left atrial volume. E/A ratio,
E0, E/E0, or S0 measured by echocardiography were not altered
by treatment with RAAS inhibition. On repeat biomarker
assessment the proportion of patients with elevated hs-cTnT
or NT-proBNP was not altered by RAAS inhibition.
Discussion
At baseline, asymptomatic patients with type 2 diabetes
mellitus and persistent microalbuminuria had increased car-
diac native T1 and ECV, reduced E0 measured by echocardio-
graphy, and elevated hs-cTnT. There was no difference in the
rates of myocardial ischemia or infarction, suggesting that the
reported differences are because of a process of microvascular
changes and myocardial extracellular ﬁbrosis rather than
occult CAD. One-year treatment with RAAS inhibition was
associated with a decrease in both ECV and improvement in LV
EF. This did not appear to be mediated by blood pressure
reduction, which was not signiﬁcantly lower on treatment.
Myocardial Tissue Composition
We report, in keeping with previous ﬁndings, that type 2
diabetes mellitus is associated with increased ECV compared
with healthy controls.19,38,39 Additionally, we demonstrate
that ACR+ve patients have higher ECV than ACRve patients
and that elevated ECV in these patients is reversible with
RAAS inhibition. These observations suggest that diffuse
cardiac ﬁbrosis could mediate heart failure risk in patients
with persistent microalbuminuria.11,12 We consciously
Table 1. Continued
Control ACRve ACR+ve
P Value Between
3 Groups
P Value for ACRve
and ACR+ve
E0 average, cm/s  8.91.9 8.21.9 0.04†
E/E0 average  7.12.3 7.22.0 0.67
S0 average, cm/s  9.72.0 9.41.8 0.45
ACE indicates angiotensin-converting enzyme; ACR, albumin:creatinine ratio; EDV, end diastolic volume; ESV, end systolic volume; HbA1c, hemoglobin A1c; hs-cTnT, high-sensitivity cardiac
troponin T; LV, left ventricle; NT-proBNP, amino terminal B type natriuretic peptide.
*Twenty-four-hour BP.
†P≤0.05.
‡Diabetes mellitus and control.
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recruited lower risk patients than previous studies (excluding
those with being treated with RAAS inhibition or insulin),
which may in part explain why ECV in diabetes mellitus
patients in the present study were not as high as previous
studies using similar methods.21
Previous studies have demonstrated that in asymptomatic
patients without known CAD, increased urinary aldosterone
levels and angiotensin II–mediated aldosterone increase are
associated with increased ECV.20 Furthermore, in a retrospec-
tive cross-sectional study of patients undergoing CMR for
clinical purposes, the use of RAAS-inhibiting medication was
associated with lower ECV.21 Ours is the ﬁrst prospective study
to show that ECV can be altered in patients with diabetes
mellitus and adds further weight to the hypothesis that
increased RAAS activity mediates diffuse ﬁbrosis, consequently
increasing heart failure risk, and that RAAS inhibition may be a
potential therapeutic intervention to ameliorate this risk.
Our ﬁndings contrast in part to those by Jellis et al in which
patients with diabetes mellitus treated with spironolactone
failed to show a reduction in ECV.40 This result may be
explained by the high use of ACE inhibitors at baseline,
exclusion of patients without diastolic dysfunction, and the
use of a now-outdated pulse sequence for the estimation of
myocardial ECV. Alternatively, it is possible that ACE
inhibitors are more effective than aldosterone blockers at
ameliorating heart failure risk in this population. On the other
hand, our results are in keeping with those of Garg et al who
have reported that microvascular function measured by
positron emission tomography improves by RAAS inhibition,
using spironolactone in asymptomatic patients with type 2
diabetes mellitus.41
Coronary Artery Disease
The patients studied were all asymptomatic with no prior
cardiac disease. However, there was still a relatively high
proportion of patients with diabetes mellitus who had prior MI
(17%). This rate at baseline was already comparable with the
15.5% Framingham predicted risk of developing coronary
disease over the subsequent 10 years. This result is also in
Figure 2. Late gadolinium enhancement (LGE) and extracellular volume (ECV) maps planned in identical
imaging planes of an ACRve patient (A and B) and ACR+ve patient (C and D). LGE imaging (A and C)
showed no focal ﬁbrosis in either patient but ECV mapping (B and D) demonstrated the ECV to be
signiﬁcantly higher in the ACR+ve patient. ACR indicates albumin:creatinine ratio.
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keeping with previous studies of patients with type 2 diabetes
mellitus, although it should be noted that patients in these
studies were not necessarily asymptomatic.24,25 Microalbu-
minuria has previously been associated with excess risk of
myocardial infarction.9,12 However, in the present study the
rate of MI was not inﬂuenced by ACR status, suggesting that it
is not the mechanism mediating increased heart failure risk in
ACR+ve patients.
Conversely, the rate of inducible ischemia detected on
adenosine stress CMR was only 4%, which is lower than
comparable studies using single-photon emission computed
tomography.42 This may reﬂect the low risk of patients in
the present study and the different sensitivity and speci-
ﬁcity of adenosine stress perfusion CMR and single-photon
emission computed tomography to detect stable CAD.34
Left Ventricular Function
Diastolic dysfunction was a common ﬁnding in our study
population (both ACR+ve and ACRve had E/A reversal), in
keeping with previous studies.17,18 However, ACR+ve patients
had a lower E0, suggesting more advanced diastolic dysfunc-
tion. Previous studies have suggested that more severe
diastolic dysfunction in diabetes mellitus predicts those who
Table 2. Clinical and Imaging Parameters Pre and Post 1 Year of Treatment with RAAS Inhibition
ACR+ve
Pre RAAS Inhibition
ACR+ve
1 Y Post RAAS Inhibition Mean Change (95% CI) P Value
N 30 30
Age (y) 62.911.5
Male sex, n (%) 26 (87)
Body mass index, kg/m2 29.94.2 29.84.4 0.04 (0.57 to 0.48) 0.87
Duration of diabetes mellitus (y) 5.04.2
HbA1c, mmol/mol 60.820.0 62.015.5 1.7 (3.5 to 6.9) 0.64
Mean 24-h systolic BP, mm Hg 13619 13220 2.9 (11.1 to 5.3) 0.67
Mean 24-h diastolic BP, mm Hg 7311 7111 2.5 (5.3 to 0.3) 0.55
Smoking 6 (20)
LV EDV, mL 148.438.7 138.937.3 9.5 (14.8 to 4.3) 0.001†
LV EDV index, mL/m2 72.316.2 67.615.9 4.7 (7.3 to 2.1) 0.001†
LV ESV, mL 62.427.5 55.425.1 7.0 (11.5 to 2.5) 0.003†
Ejection fraction, % 59.37.8 61.58.7 2.2 (0.2 to 4.3) 0.03†
LV mass, g 111.127.4 112.754.6 1.6 (1.5 to 4.7) 0.30
LV mass index, g/m2 54.010.8 54.611.3 0.6 (1.0 to 2.2) 0.46
Mass/end diastolic volume, g/mL 0.760.13 0.830.28 0.07 (0.03 to 0.11) 0.002†
Left atrial volume, mL 91.325.8 89.328.0 2.7 (9.2 to 3.9) 0.41
Left atrial volume index, mL/m2 44.511.0 43.512.2 1.3 (4.4 to 1.7) 0.38
Native T1, ms 1243.058.5 1251.440.9 8.3 (13.4 to 30.1) 0.44
Extracellular volume, % 26.53.6 25.23.1 1.3 (2.3 to 0.3) 0.01†
Evidence of prior myocardial infarction, n (%) 8 (27) 9 (30) 0.50
Serum aldosterone, pmol/L 337.0192.7 244.3137.4 92.7 (176.2 to 9.1) 0.03†
hs-cTnT ≥14 ng/L, n (%) 6 (20) 8 (27) 0.76
NT-proBNP ≥125 ng/L, n (%) 4 (13) 7 (23) 0.51
E/A ratio 0.820.35 0.840.27 0.02 (0.10 to 0.14) 0.71
E0 average, cm/s 8.11.7 8.12.4 0.04 (0.65 to 0.74) 0.90
E/E0 average 7.11.5 7.42.4 0.30 (0.54 to 1.13) 0.48
S0 average, cm/s 9.22.0 9.41.9 0.1 (0.7 to 1.0) 0.72
ACE indicates angiotensin-converting enzyme; ACR, albumin:creatinine ratio; EDV, end diastolic volume; ESV, end systolic volume; HbA1c, hemoglobin A1c; hs-cTnT, high-sensitivity cardiac
troponin T; LV, left ventricle; NT-proBNP, amino terminal B type natriuretic peptide; RAAS, renin-angiotensin-aldosterone system.
†P≤0.05.
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are likely to go on to develop clinically important heart
failure.43 We have also identiﬁed that diabetes mellitus is
associated with concentric remodeling of the left ventri-
cle,16,44 although there were no differences between ACR+ve
and ACRve patients.
Treatment with RAAS inhibition was associated with a
modest improvement in systolic function, although there were
no signiﬁcant changes in diastolic function measured by
echocardiography. This is in keeping with the observation that
RAAS inhibition is a much better treatment for heart failure
with reduced EF than with preserved EF and diastolic
dysfunction.45
Interestingly, RAAS inhibition was not associated with a
decrease in LV mass. It is well recognized that there is a
strong correlation between blood pressure and LV mass.16,46
The mean dose of RAAS inhibition equivalent to ramipril was
4.6 mg, which reﬂects the difﬁculties in clinical practice of
uptitration, and it is possible that higher doses of RAAS
inhibition would be associated with a greater reduction of
blood pressure and consequently LV mass.
Biomarkers
Microalbuminuria has been used for some time as a screening
biomarker to identify patients with diabetes mellitus with
increased cardiovascular risk,30 and current guidelines sug-
gest that those with persistent microalbuminuria should
receive intensive cardiac preventative medication (although
the cut-offs used to diagnose microalbuminuria vary between
guidelines).47 However, though ACR is a powerful screening
tool, there can be wide variations between repeated mea-
surements and ACR can be falsely elevated in the presence of
glycosuria, infection, strenuous exercise, fever, and menstru-
ation.48
Patients with type 2 diabetes mellitus have elevated levels of
both hs-cTnT and NT-proBNP, which appear to be predictive of
adverse cardiovascular events including heart failure.27–29
However, previous studies that have demonstrated their prog-
nostic utility have not included comprehensive cardiac imaging
and the exactmechanismof theprocesses leading tomyocardial
injury and biomarker release was not fully understood. We have
demonstrated that in ACR+ve patients both hs-cTnT andECV are
elevated, suggesting that they are both markers of a diffuse
cardiac ﬁbrotic process rather than occult CAD. Future
randomized studies are needed to establish whether ECV, hs-
cTnT, or diastolic dysfunction themselves or the associated
adverse prognosis can be altered by intervention.
Limitations
This study was a nonblinded observational study, and the
results need to be conﬁrmed in a larger blinded randomized
cohort. Furthermore, the study was not powered to investi-
gate the prevalence of silent CAD or heart failure end points
but did include multiple surrogate imaging end points. We
have not carried out coronary angiography because this
invasive procedure would not be ethically appropriate in
asymptomatic low-risk patients. However, stress perfusion
imaging excluded signiﬁcant silent ischemia in these patients
and therefore CAD is unlikely to be responsible for our
ﬁndings. For the same reasons, we did not carry out
myocardial biopsy to conﬁrm increased extracellular matrix
histologically. However, ECV measured by CMR has been
validated against histology in other disease processes33 and
in animal models of diabetes mellitus.49 We did not perform
echocardiography or biomarker assessment on the healthy
controls, although normal ranges exist for these parameters.
Conclusions
Asymptomatic patients with type 2 diabetes mellitus and
persistent microalbuminuria have several markers suggestive
of diffuse cardiac ﬁbrosis including elevated ECV, hs-cTnT, and
diastolic dysfunction. The prevalence of silent myocardial
ischemia or infarction was not inﬂuenced by ACR status.
Treatment with an ACE inhibitor was associated with
improvement in LV EF and ECV regression. These ﬁndings
suggest that increased risk in this patient group is mediated
by subclinical changes in tissue structure and function rather
than occult CAD, which may have implications for the
management of these patients.
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